|
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ERBB2IP |
Gene summary for ERBB2IP |
| Gene information | Species | Human | Gene symbol | ERBB2IP | Gene ID | 55914 |
| Gene name | erbb2 interacting protein | |
| Gene Alias | ERBB2IP | |
| Cytomap | 5q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q96RT1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55914 | ERBB2IP | P65T-E | Human | Esophagus | ESCC | 9.61e-28 | 4.55e-01 | 0.0978 |
| 55914 | ERBB2IP | P74T-E | Human | Esophagus | ESCC | 1.21e-21 | 4.68e-01 | 0.1479 |
| 55914 | ERBB2IP | P75T-E | Human | Esophagus | ESCC | 3.87e-34 | 5.57e-01 | 0.1125 |
| 55914 | ERBB2IP | P76T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.59e-01 | 0.1207 |
| 55914 | ERBB2IP | P79T-E | Human | Esophagus | ESCC | 6.56e-15 | 2.59e-01 | 0.1154 |
| 55914 | ERBB2IP | P80T-E | Human | Esophagus | ESCC | 7.27e-30 | 6.18e-01 | 0.155 |
| 55914 | ERBB2IP | P82T-E | Human | Esophagus | ESCC | 9.88e-21 | 7.46e-01 | 0.1072 |
| 55914 | ERBB2IP | P83T-E | Human | Esophagus | ESCC | 1.53e-26 | 5.96e-01 | 0.1738 |
| 55914 | ERBB2IP | P84T-E | Human | Esophagus | ESCC | 2.04e-06 | 3.74e-01 | 0.0933 |
| 55914 | ERBB2IP | P89T-E | Human | Esophagus | ESCC | 6.02e-08 | 4.37e-01 | 0.1752 |
| 55914 | ERBB2IP | P91T-E | Human | Esophagus | ESCC | 1.72e-16 | 9.48e-01 | 0.1828 |
| 55914 | ERBB2IP | P94T-E | Human | Esophagus | ESCC | 6.05e-03 | 4.95e-01 | 0.0879 |
| 55914 | ERBB2IP | P104T-E | Human | Esophagus | ESCC | 8.26e-10 | 5.63e-01 | 0.0931 |
| 55914 | ERBB2IP | P107T-E | Human | Esophagus | ESCC | 4.05e-26 | 4.74e-01 | 0.171 |
| 55914 | ERBB2IP | P126T-E | Human | Esophagus | ESCC | 1.79e-11 | 6.83e-01 | 0.1125 |
| 55914 | ERBB2IP | P127T-E | Human | Esophagus | ESCC | 4.12e-31 | 5.39e-01 | 0.0826 |
| 55914 | ERBB2IP | P128T-E | Human | Esophagus | ESCC | 7.44e-15 | 4.02e-01 | 0.1241 |
| 55914 | ERBB2IP | P130T-E | Human | Esophagus | ESCC | 6.36e-70 | 1.22e+00 | 0.1676 |
| 55914 | ERBB2IP | C04 | Human | Oral cavity | OSCC | 6.50e-08 | 4.25e-01 | 0.2633 |
| 55914 | ERBB2IP | C21 | Human | Oral cavity | OSCC | 2.97e-34 | 8.68e-01 | 0.2678 |
| Page: 1 2 3 4 5 6 |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD | ![]() |
| Colorectum | SER | ![]() |
| Colorectum | MSS | ![]() |
| Colorectum | MSI-H | ![]() |
| Colorectum | FAP | ![]() |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
| hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
| hsa046212 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
| hsa0462111 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
| hsa046214 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
| hsa046215 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
| hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
| hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |